Dupilumab for Eosinophilic Esophagitis in Adolescents and Adults: Real-World Outcomes Across Different Dosing Regimens from the EoE CONNECT Registry - PubMed
2 hours ago
- #Eosinophilic Esophagitis
- #Real-World Evidence
- #Dupilumab
- Dupilumab showed real-world effectiveness for eosinophilic esophagitis (EoE), reducing peak eosinophil counts, EREFS scores, and dysphagia symptom scores significantly after a median of 6.5 months.
- Both weekly and semi-weekly dosing regimens (300 mg) were equally effective, with clinico-histological response rates of 86.0% and 81.2%, respectively.
- Severe atopy was the strongest predictor for choosing a semi-weekly regimen, with other predictors including conjunctivitis, asthma, and multiple food allergies.
- Dose adjustments were successful: tapering from weekly to semi-weekly or monthly maintained efficacy in all cases, while escalating from semi-weekly to weekly rescued 80% of non-responders.
- Treatment discontinuation was low (5%), primarily due to adverse events, indicating good tolerability in a real-world setting.